stem cell image

An innovative, Cell Therapy based CDMO Announces the Expansion of its Facility

Lykan Bioscience, a contract development and manufacturing organisation specialising in cell-based therapeutics, announced the expansion of its facility in Hopkinton, Massachusetts. The increasing need for cell therapy process research and production is driving the expansion and establishment of new innovation lab. As part of the facility expansion plan, seven ISO 7 cGMP suites with autologous […]

WuXi ATU Opens New Facility in Philadelphia for Advanced Therapies Testing

by

Excerpt WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, has announced the official launch of its testing facility located in Philadelphia’s Navy Yard. Article Summary The new facility with 140,000 square feet of labs, will improve the firm’s Contract Testing, Development, and Manufacturing Organization business model by expanding the previous testing capacity. This will allow the company to meet […]

Lykan Bioscience to Increase Its Cell Therapy Process Development and Manufacturing Capacity by 90%

by

Excerpt Lykan Bioscience, a contract development and manufacturing organisation specialising in cell-based therapeutics, announced the expansion of its facility in Hopkinton, Massachusetts. The increasing need for cell therapy process research and production is driving the expansion and establishment of new innovation lab. Article Summary As part of the facility expansion plan, seven ISO 7 cGMP suites with autologous and allogeneic […]

Sanofi Invests $60 Million in an Eye-Focused Gene Therapy Biotech Company

by

Excerpt Sanofi is investing up to $60 million in a UK based gene therapy start up, Gyroscope Therapeutics. The company is developing therapies for a prevalent form of blindness. The funds are raised after the firm announced positive safety data from their gene – therapy (GT005). Article Summary Gyroscope was founded by U.K. based healthcare investment business – Syncona Ltd. Syncona […]

Blackstone Life Sciences Supports Autolus Therapeutics with $250 Million Investment

by

Excerpt Autolus Therapeutics plc, a clinical-stage biopharmaceutical company that develops cell therapies for cancer treatment has announced a financial agreement with Blackstone Life Sciences for $250 million. Article Summary Autolus will receive up to $250 million in equity and product financing from Blackstone which will enable the development of CART cell therapy product – obecabtagene autoleucel (obe-cel), […]

Adaptimmune Enters into a Strategic Collaboration with Genentech

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

Excerpt An agreement between Adaptimmune and Genentech is set to drive “off-the-shelf” cancer-targeted cell therapy advancements and commercialization with an initial payment of $150 million to Adaptimmune. The partnership also aims to develop a first-of-its-kind personalized cell therapy platform to enable patients to receive curated T-cell products for their individual cancer treatment needs. Adaptimmune may […]

cell therapy blog image

Notable Players in the APAC Cell Therapy Manufacturing Space

by

Excerpt Key drivers such as fund and regulatory support from the government, improved market access and healthcare infrastructure and more are currently fueling growth in APAC’s cell therapy market. The enactment of the Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine in August 2020, the increased market access can be […]

Cytovia-Therapeutics-Logo

Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline

by

Excerpt $45 million in financing has been secured by Cytovia and its China-focused joint venture CytoLynx, to advance their Natural Killer (NK) cell therapy for global commercialisation. TF Capital, together with Cytovia, have formed CytoLynx, and the venture is further supported by YF Capital, BioTrack Capital, Ruihua Capital and YG Sino-Dragon Fund. This will accelerate […]

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

by

Excerpt Positive interim analysis of safety and efficacy from the first 30% of enrolled patients evaluated 12 months post-treatment in a Phase 3 clinical trial (SALAMANDER) of REX-001 has resulted in the independent Data Monitoring Committee (DMC) recommending the unchanged continuation of the trial. REX-001, an autologous multi-cell therapy (MCT), is being developed for the […]

Tree Frog Therapeutics Blog

TreeFrog Therapeutics secures $75m in Series B financing to advance a pipeline of Stem Cell-Derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan

by

Excerpt Pursuant to securing $75 million in Series B funding, TreeFrog Therapeutics names Frederic Desdouits, PhD, as CEO and announces that co-founder Kevin Alessandri, PhD, is to relocate to Boston to drive TreeFrog’s expansion in the U.S. The funding was led by Bpifrance Large Venture, together with Leonard Green & Partners L.P., Bristol Myers Squibb […]

Updated Biothera Blog

Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)

Excerpt Bio-Thera Solutions and Sandoz have entered a commercialisation and license agreement for BAT1706, a monoclonal antibody that is a proposed biosimilar referencing AVASTIN® (bevacizumab). Under the terms of the agreement, Bio-Thera will develop, manufacture and supply BAT1706 and Sandoz will market the bevacizumab biosimilar in markets covered by the agreement.  Article Bio-Thera Solutions has […]

AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie and REGENXBIO Announce Eye Care Collaboration

Excerpt AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach […]

bag